Simple TruthI have positioned myself in this company over the past three and a half years.The simple truth is that the latest Health Canada Approval marks the first opportunity for us to market our final development as a four chamber heart volume assessment technology. Our approach to assessing heart condition certainly saves time, money, lives and allows for greater access to MRI machines for other diagnostic purposes. This technology has been proven to be reliable as a diagnostic tool by unrelated third party validation studies. The one question whose answer will determine what our company is worth:: "Will the medical industry embrace it?" The medical industry does not readily embrace directions that are not considered the status quo, especially when it comes from a small venture company such as Ventripoint. If, however we are able to gain traction through acceptance and adoption of our technology, a one dollar share price will be a milestone that will seem insignificant to where the market cap of this company will end up.